Canbridge Pharmaceuticals Inc
HKEX:1228
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Canbridge Pharmaceuticals Inc
HKEX:1228
|
CN |
|
Z
|
Zhejiang Xinao Textiles Inc
SSE:603889
|
CN |
|
Fujikon Industrial Holdings Ltd
HKEX:927
|
HK |
|
N
|
Nielsen Holdings PLC
LSE:0XI7
|
US |
Canbridge Pharmaceuticals Inc
CANbridge Pharmaceuticals Inc. operates as a rare disease-focused biopharmaceutical company committed to the research, development and commercialization of transformative therapies. The company is headquartered in Beijing, Beijing. The company went IPO on 2021-12-10. The firm's main businesses are the development, production, promotion and sales of medical products. The firm's main product is the glycosylated fusion protein CAN008 for the treatment of glioblastoma (GBM). The firm's products are mainly used in rare diseases such as Hunter's syndrome (MPS II), rare tumors and other fields. The firm is also engaged in the development of gene therapy.
CANbridge Pharmaceuticals Inc. operates as a rare disease-focused biopharmaceutical company committed to the research, development and commercialization of transformative therapies. The company is headquartered in Beijing, Beijing. The company went IPO on 2021-12-10. The firm's main businesses are the development, production, promotion and sales of medical products. The firm's main product is the glycosylated fusion protein CAN008 for the treatment of glioblastoma (GBM). The firm's products are mainly used in rare diseases such as Hunter's syndrome (MPS II), rare tumors and other fields. The firm is also engaged in the development of gene therapy.
